Pfizer’s Selzentry Poised To Be Most Expensive First-Line AIDS Drug

Responding to today’s news that the Food and Drug Administration (FDA) Antiviral Advisory Committee has approved Pfizer Inc.’s AIDS therapy, Selzentry (maraviroc), for use in therapy-naïve patients, AIDS Healthcare Foundation (AHF) strongly criticized Pfizer for its current pricing of the drug at an Average Wholesale Price (AWP) of $13,767 per-patient per-year-which, if this price remains when use is expanded, would make it the most expensive first-line AIDS drug on the market.

Source: Pfizer’s Selzentry Poised To Be Most Expensive First-Line AIDS Drug